{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:59:31Z","timestamp":1762624771536},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vifor Pharma Espa\u00f1a S.L.U."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The objective of the FeminFER project was to assess the value of ferric carboxymaltose following a multicriteria decision analysis in obstetrics and gynaecology in Spain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ferric carboxymaltose (FCM) and ferrous sulphate were evaluated using the EVIDEM framework. Ten stakeholders participated to collect different perspectives. The framework was adapted considering evidence retrieved with a PICO-S search strategy and grey literature. Criteria\/subcriteria were weighted by level of relevance and an evidence-based decision-making exercise was developed in each criterion; weights and scores were combined to obtain the value of intervention relative to each criterion\/subcriterion, that were further combined into the Modulated Relative Benefit-Risk Balance (MRBRB).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The most important criterion favouring FCM was Compared Efficacy\/Effectiveness (0.183\u2009\u00b1\u20090.07), followed by Patient Preferences (0.059\u2009\u00b1\u20090.10). Only Direct medical costs criterion favoured FS (-0.003\u2009\u00b1\u20090.03). MRBRB favoured FCM; 0.45\u2009\u00b1\u20090.19; in a scale from -1 to\u2009+\u20091.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, considering the several criteria involved in the decision-making process, participants agreed with the use of FCM according to its MRBRB.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-022-04481-w","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T15:02:54Z","timestamp":1645801374000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Applying reflective multicriteria decision analysis to understand the value of therapeutic alternatives in the management of gestational and peripartum anaemia in Spain"],"prefix":"10.1186","volume":"22","author":[{"given":"Manel","family":"Casellas Caro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas Cancelo","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Garc\u00eda-Erce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Baquero \u00dabeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Gl\u00f2ria","family":"Torras Boatella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Gredilla D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Ruano Encinar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Mart\u00edn Bay\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Nicol\u00e1s Pic\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Eduardo","family":"Arjona Berral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Mu\u00f1oz Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Jim\u00e9nez Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Cerezales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Cuervo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"4481_CR1","unstructured":"World Health Organization. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. 2020. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240000124"},{"key":"4481_CR2","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2214-109X(13)70001-9","volume":"1","author":"GA Stevens","year":"2013","unstructured":"Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995\u20132011: A systematic analysis of population-representative data. Lancet Glob Heal. 2013;1:e16\u201325. https:\/\/doi.org\/10.1016\/S2214-109X(13)70001-9.","journal-title":"Lancet Glob Heal"},{"key":"4481_CR3","doi-asserted-by":"publisher","unstructured":"Otamendi Goicoechea I, Zalba Marcos S, Ascensi\u00f3n Zabalegui Goicoechea M, Galbete A, Osinaga Alcaraz M, Garc\u00eda Erce JA. Prevalencia de anemia en poblaci\u00f3n gestante. Med Clin (Barc). 2021 [cited 12 Apr 2021]. doi:https:\/\/doi.org\/10.1016\/j.medcli.2021.02.005","DOI":"10.1016\/j.medcli.2021.02.005"},{"key":"4481_CR4","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00404-017-4526-2","volume":"296","author":"C Breymann","year":"2017","unstructured":"Breymann C, Honegger C, H\u00f6sli I, Surbek D. Diagnosis and treatment of iron-deficiency anaemia in pregnancy and postpartum. Arch Gynecol Obstet. 2017;296:1229\u201334. https:\/\/doi.org\/10.1007\/s00404-017-4526-2.","journal-title":"Arch Gynecol Obstet"},{"key":"4481_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ijgo.12740","volume":"144","author":"GC Di Renzo","year":"2019","unstructured":"Di Renzo GC, Gratacos E, Kurtser M, Malone F, Nambiar S, Sierra N, et al. Good clinical practice advice: Iron deficiency anemia in pregnancy. Int J Gynecol Obstet. 2019;144:322\u20134. https:\/\/doi.org\/10.1002\/ijgo.12740.","journal-title":"Int J Gynecol Obstet"},{"key":"4481_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.siny.2006.10.007","volume":"12","author":"R Rao","year":"2007","unstructured":"Rao R, Georgieff MK. Iron in fetal and neonatal nutrition. Semin Fetal Neonatal Med. 2007;12:54\u201363. https:\/\/doi.org\/10.1016\/j.siny.2006.10.007.","journal-title":"Semin Fetal Neonatal Med"},{"key":"4481_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/tme.12443","volume":"28","author":"M Mu\u00f1oz","year":"2018","unstructured":"Mu\u00f1oz M, Pe\u00f1a-Rosas JP, Robinson S, Milman N, Holzgreve W, Breymann C, et al. Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. Transfus Med. 2018;28:22\u201339. https:\/\/doi.org\/10.1111\/tme.12443.","journal-title":"Transfus Med"},{"key":"4481_CR8","doi-asserted-by":"publisher","unstructured":"Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2019; bjh.16221. doi:https:\/\/doi.org\/10.1111\/bjh.16221","DOI":"10.1111\/bjh.16221"},{"key":"4481_CR9","doi-asserted-by":"publisher","unstructured":"Garcia-Erce JA, Alt\u00e9s A, L\u00f3pez Rubio M, Remacha \u00c1F, En representaci\u00f3n del Grupo Espa\u00f1ol de Eritropatolog\u00eda de la Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia. Management of iron deficiency in various clinical conditions and the role of intravenous iron: Recommendations of the Spanish Erythropathology Group of the Spanish Society of Haematology and Haemotherapy. 2019. https:\/\/doi.org\/10.1016\/j.rce.2019.09.004","DOI":"10.1016\/j.rce.2019.09.004"},{"key":"4481_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejogrb.2018.03.005","volume":"224","author":"J Estadella","year":"2018","unstructured":"Estadella J, Villamar\u00edn L, Feliu A, Perell\u00f3 J, Calaf J. Characterization of the population with severe iron deficiency anemia at risk of requiring intravenous iron supplementation. Eur J Obstet Gynecol Reprod Biol. 2018;224:41\u20134. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.03.005.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"4481_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1053\/j.seminhematol.2018.04.006","volume":"55","author":"AA Khalafallah","year":"2018","unstructured":"Khalafallah AA, Hyppa A, Chuang A, Hanna F, Wilson E, Kwok C, et al. A prospective randomised controlled trial of a single intravenous infusion of ferric carboxymaltose vs single intravenous iron polymaltose or daily oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy. Semin Hematol. 2018;55:223\u201334. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.04.006.","journal-title":"Semin Hematol"},{"key":"4481_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1515\/jpm-2016-0050","volume":"45","author":"C Breymann","year":"2017","unstructured":"Breymann C, Milman N, Mezzacasa A, Bernard R, Dudenhausen J. Ferric carboxymaltose vs oral iron in the treatment of pregnant women with iron deficiency anemia: An international open-label randomized controlled trial (FER-ASAP). J Perinat Med. 2017;45:443\u201353. https:\/\/doi.org\/10.1515\/jpm-2016-0050.","journal-title":"J Perinat Med"},{"issue":"435","key":"4481_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2008.07.046","volume":"199","author":"MH Seid","year":"2008","unstructured":"Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(435):e1-435.e7. https:\/\/doi.org\/10.1016\/j.ajog.2008.07.046.","journal-title":"Am J Obstet Gynecol"},{"key":"4481_CR14","doi-asserted-by":"publisher","unstructured":"Seid MH, Butcher AD, Chatwani A. Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia. Anemia. 2017 [cited 9 Mar 2020]. doi:https:\/\/doi.org\/10.1155\/2017\/9642027","DOI":"10.1155\/2017\/9642027"},{"key":"4481_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/SLA.0000000000001646","volume":"264","author":"B Froessler","year":"2016","unstructured":"Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery. Ann Surg. 2016;264:41\u20136. https:\/\/doi.org\/10.1097\/SLA.0000000000001646.","journal-title":"Ann Surg"},{"key":"4481_CR16","first-page":"499","volume":"3","author":"SD Joshi","year":"2016","unstructured":"Joshi SD, Mathapati S. Ferric carboxymaltose a safe and effective alternative in correcting iron deficiency anemia prior to major elective gynecological surgeries. Eur J Biomed Phamaceutical Sci. 2016;3:499\u2013503.","journal-title":"Eur J Biomed Phamaceutical Sci"},{"key":"4481_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/bja\/aer242","volume":"107","author":"E Bisbe","year":"2011","unstructured":"Bisbe E, Garcia-Erce JA, D\u00edez-Lobo AI, Mu\u00f1oz M. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth. 2011;107:477\u20138. https:\/\/doi.org\/10.1093\/bja\/aer242.","journal-title":"Br J Anaesth"},{"key":"4481_CR18","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1016\/j.jmig.2015.08.755","volume":"22","author":"J Nores","year":"2015","unstructured":"Nores J. The Efficacy of IV Ferric Carboxymaltose in the Perioperative Management of Moderate to Severe Iron Deficiency Anemia. J Minim Invasive Gynecol. 2015;22:S211\u20132. https:\/\/doi.org\/10.1016\/j.jmig.2015.08.755.","journal-title":"J Minim Invasive Gynecol"},{"key":"4481_CR19","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1213\/ANE.0000000000003583","volume":"127","author":"I Ellermann","year":"2018","unstructured":"Ellermann I, Bueckmann A, Eveslage M, Buddendick H, Latal T, Niehoff D, et al. Treating anemia in the preanesthesia assessment clinic: Results of a retrospective evaluation. Anesth Analg. 2018;127:1202\u201310. https:\/\/doi.org\/10.1213\/ANE.0000000000003583.","journal-title":"Anesth Analg"},{"key":"4481_CR20","unstructured":"Hospital Universitario Reina Sof\u00eda. Hierro carboximaltosa. Informe de la Comisi\u00f3n de Farmacia y Terap\u00e9utica. 2013. Available: https:\/\/www.sspa.juntadeandalucia.es\/servicioandaluzdesalud\/hrs3\/fileadmin\/user_upload\/area_atencion_alprofesional\/comision_farmacia\/informes\/hierro_carboximaltosa_2013.pdf"},{"key":"4481_CR21","unstructured":"Direcci\u00f3n de atenci\u00f3n y evaluaci\u00f3n sanitaria. Comisi\u00f3n de uso racional de los medicamentos y productos sanitarios. Resoluci\u00f3n de la Comisi\u00f3n de uso racional de los medicamentos y productos sanitarios (CURMP) sobre los medicamentos incluidos en la gu\u00eda farmacoterap\u00e1utica del SESPA: Hierro intravenoso dosis altas. Oviedo; 2020. Available: https:\/\/www.astursalud.es\/documents\/31867\/954826\/HIERRO+INTRAVENOSO_DICTAMEN_+03_2020.pdf\/f50d5484-638a-6f34-6885-12d77103b70c"},{"key":"4481_CR22","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.healthpol.2020.07.007","volume":"124","author":"C Whichello","year":"2020","unstructured":"Whichello C, Bywall KS, Mauer J, Stephen W, Cleemput I, Pinto CA, et al. An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process? Health Policy (New York). 2020;124:1325\u201332. https:\/\/doi.org\/10.1016\/j.healthpol.2020.07.007.","journal-title":"Health Policy (New York)"},{"key":"4481_CR23","unstructured":"EVIDEM | A reflective framework to advance health. [cited 3 Jul 2020]. Available: https:\/\/www.evidem.org\/"},{"key":"4481_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12325-017-0653-1","volume":"35","author":"M Wagner","year":"2018","unstructured":"Wagner M, Samaha D, Khoury H, O\u2019Neil WM, Lavoie L, Bennetts L, et al. Development of a framework based on reflective MCDA to support patient-clinician shared decision-making: the case of the management of gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the United States. Adv Ther. 2018;35:81\u201399. https:\/\/doi.org\/10.1007\/s12325-017-0653-1.","journal-title":"Adv Ther"},{"key":"4481_CR25","doi-asserted-by":"publisher","unstructured":"Moreno-Calder\u00f3n A, Tong TS, Thokala P. Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review. PharmacoEconomics. Adis; 2020;269\u2013283. https:\/\/doi.org\/10.1007\/s40273-019-00863-9","DOI":"10.1007\/s40273-019-00863-9"},{"key":"4481_CR26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s12325-018-0745-6","volume":"35","author":"M Wagner","year":"2018","unstructured":"Wagner M, Samaha D, Cuervo J, Patel H, Martinez M, O\u2019Neil WM, et al. Applying reflective multicriteria decision analysis (MCDA) to patient-clinician shared decision-making on the management of gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the Spanish context. Adv Ther. 2018;35:1215\u201331. https:\/\/doi.org\/10.1007\/s12325-018-0745-6.","journal-title":"Adv Ther"},{"key":"4481_CR27","doi-asserted-by":"publisher","unstructured":"Guarga L, Badia X, Obach M, Fontanet M, Prat A, Vallano A, et al. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut). Orphanet J Rare Dis. 2019;14. https:\/\/doi.org\/10.1186\/s13023-019-1121-6","DOI":"10.1186\/s13023-019-1121-6"},{"key":"4481_CR28","unstructured":"Remacha \u00c1F, Alt\u00e9s A, Garc\u00eda Erce JA, L\u00f3pez Rubio M, de la O Ab\u00edo M, Ben\u00e9itez D, et al. Manejo del d\u00e9ficit de hierro en distintas situaciones cl\u00ednicas.\u00a0Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia: Papel del hierro intravenoso; 2018.\u00a0Available: https:\/\/www.sehh.es\/publicaciones\/guias-y-documentos\/123091-manejo-del-deficit-de-hierro-en-distintas-situaciones-clinicas-papel-del-hierrointravenoso."},{"key":"4481_CR29","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1 (updated September 2020). Cochrane Training. 2020. Available: https:\/\/training.cochrane.org\/handbook\/current","DOI":"10.1002\/9781119536604"},{"key":"4481_CR30","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/"},{"key":"4481_CR31","unstructured":"European Medicines Agency. Available: https:\/\/www.ema.europa.eu\/en"},{"key":"4481_CR32","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Available: https:\/\/www.aemps.gob.es\/"},{"key":"4481_CR33","unstructured":"AWGE \u2013 Anemia Working Group Espa\u00f1a. [cited 3 Jul 2020]. Available: https:\/\/awge.doctime.es\/"},{"key":"4481_CR34","unstructured":"Nataonline. [cited 3 Jul 2020]. Available: https:\/\/nataonline.com\/"},{"key":"4481_CR35","unstructured":"Bay\u00f3n Yusta J, Guti\u00e9rrez Iglesias A, Galnares-Cordero L, Guti\u00e9rrez-Ibarlueza I. Proyecto metodol\u00f3gico. S\u00edntesis de informaci\u00f3n relevante de apoyo a los MCDA (an\u00e1lisis de decisi\u00f3n multicriterio) para la toma de decisiones. 2019. Available: https:\/\/www.euskadi.eus\/gobierno-vasco\/-\/libro\/sintesis-de-informacion-relevante-de-apoyo-a-los-mcda-analisis-de-decision-multicriterio-para-la-toma-de-decisiones-proyecto-metodologico\/"},{"key":"4481_CR36","unstructured":"M\u00e1rquez-Pel\u00e1ez S, Esp\u00edn Balbino J, Olry de Labry Lima A, Ben\u00edtez Hidalgo V, grupo de trabajo Redets para MCDA. Gu\u00eda para la elaboraci\u00f3n de recomendaciones basada en an\u00e1lisis de decisi\u00f3n multicriterio. Sevilla; 2020. Available: https:\/\/www.aetsa.org\/2020\/09\/18\/aetsa-guia-para-la-elaboracion-de-recomendaciones-basadas-en-analisis-de-decision-multicriterio-mcda\/"},{"key":"4481_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.medcli.2016.01.029","volume":"146","author":"XU iBrichs","year":"2016","unstructured":"iBrichs XU, Carballeira MR, Fern\u00e1ndez AG, Pica\u00f1ol EP. Anemia en el embarazo y el posparto inmediato Prevalencia y factores de riesgo. Med Clin (Barc). 2016;146:429\u201335.","journal-title":"Med Clin (Barc)"},{"key":"4481_CR38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00404-019-05374-8","volume":"301","author":"D Surbek","year":"2020","unstructured":"Surbek D, Vial Y, Girard T, Breymann C, Bencaiova GA, Baud D, et al. Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion. Arch Gynecol Obstet. 2020;301:627\u201341. https:\/\/doi.org\/10.1007\/s00404-019-05374-8.","journal-title":"Arch Gynecol Obstet"},{"key":"4481_CR39","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1111\/trf.15930","volume":"60","author":"NR Guinn","year":"2020","unstructured":"Guinn NR, Cooter ML, Maisonave Y, Grimsley A, Cellura C, Grotegut CA, et al. How do I develop a process to effectively treat parturients with iron deficiency anemia? Transfusion. 2020;60:2476\u201381. https:\/\/doi.org\/10.1111\/trf.15930.","journal-title":"Transfusion"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-022-04481-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-022-04481-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-022-04481-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T15:04:56Z","timestamp":1645801496000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-022-04481-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4481"],"URL":"https:\/\/doi.org\/10.1186\/s12884-022-04481-w","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"2 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with national regulations in force, ethics approval and consent to parcipate were not required (Law LEY 14\/2007, de 3 de julio, de Investigaci\u00f3n biom\u00e9dica; and Orden SAS\/3470\/2009, de 16 de diciembre, por la que se publican las directrices sobre estudios posautorizaci\u00f3n de tipo observacional para medicamentos de uso humano).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.C.C., M.J.C.H., J.L.B.U., M.G.T.B., E.G.D., M.R.E, I.M.B, J.N.P., J.E.A.B., A.M.S. and Axentiva Solutions S.L. received consulting fees from Vifor Pharma Espa\u00f1a S.L.U. J.A.G.E has received research funding, consulting fees, reimbursment for speaking at conferences, or travel grants from Vifor Pharma, Sandoz, Zambon, Octapharma, CSL-Behring, and Fresenius. S.J.M. is an employee at Vifor Pharma Espa\u00f1a S.L.U. MC and JC work for a consulting firm being hired by Vifor Pharma Espa\u00f1a. The rest of the authors declare no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}